ICON (ICLR) Q1 FY26 earnings call: guidance and Q&A

Why did the spread between backlog and performance obligations widen, and is it due to new awards not yet contracted or adjustments to contracted awards?

The widening spread is due to strong book-to-bill (new awards not yet contracted) and Q1 being seasonally weaker for signings. Q2 is expected to be a very strong quarter for signings, which should shift this number.

“It's two things. As you rightly say, it's strong book-to-bill right back to back. So you're going to see some drag there. The other side of it is seasonality-wise, Q1 is not always the strongest quarter for signings. I will tell you that Q2 is looking like a very strong quarter for signings. So I'd expect a significant shift in that number in the Q2 print.”

asked by Eric Coldwell · answered by Barry Balfe

Management commented on expecting higher cancellations going forward despite low Q1 levels. Could you elaborate on this and what's seen in Q2 so far?

Q1's cancellation rate of $383 million was notably low and not a guaranteed run rate, with historical averages suggesting $500 million-$600 million. Q2 cancellations will be higher than Q1 but not at concerning levels.

“My comment really is only intended to reflect that. I don't think anyone should take an exceptionally low canceled quarter and call at par by default. Regarding your question about Q2, Q2 will take up a bit. certainly nothing like the concerning levels of cancellations we saw in the past. But as I've been saying for a while, it cancels bands around between, I don't know, $500 million and $600 million, I don't think that's going to be out of the ordinary for a business of our size.”

asked by Michael Ryskin · answered by Barry Balfe

Can you provide more color on the quality of the pipeline, including labs and Phase 1 contribution, and if pricing reflects this quality?

The pipeline quality is encouraging, focusing on convertibility and profitability. New midsized and labs partnerships were secured, and there's a skew towards Phase III trials. Pricing environment remains consistent, with ICON focusing on value creation through superior execution rather than price concessions.

“I mean the way we think about demand is not simply volume of demand. We're focused on convertibility of the pipeline we see quality opportunities, we can turn into significant revenue that drive significant profitability. We're reasonably encouraged to be candid. I mean, adding a new midsized partnership in the quarter, labs partnership in large pharma the quarter, albeit they didn't particularly contribute to awards in the quarter, I think, is encouraging.”

asked by David Windley · answered by Barry Balfe

How confident is management in the embedded margin ramp in guidance, and what's the split between direct costs, SG&A, and mix-related contributions?

EBITDA margin for Q2 is anticipated around 16%. Margin expansion through the year will be driven by mitigating mix impacts (increased direct fee growth, FSO vs. FSP) and cost actions, with the latter contributing more heavily in the second half. The focus is on margin dollars over percentage due to pass-through volatility.

“Having said that, looking at Q2, particularly where we are now, at this stage in the quarter, we would anticipate some continued margin progression in the second quarter, some somewhere in the order of about 0.5% or so. So EBITDA margin for Q2 of somewhere and around 16%. Then from there through the balance of the year, we will continue to focus on executing.”

asked by Michael Cherny · answered by Nigel Clerkin

How does Q2 demand compare to Q1, particularly regarding pharma vs. biotech strength, and how should we think about Q2 demand relative to the initial guidance?

Demand is broadly comparable quarter-over-quarter, with pharma strong in Q1 and biotech stronger in Q2. Management aims to sustain commercial performance, with direct fee book-to-bill above 1.2x. Strong Q2 bookings are more relevant for 2027 financials than 2026, as the full-year guidance already factored in Q1's performance and assumes a ~1.0 book-to-bill for the rest of the year.

“Demand is broadly comparable. It's always dangerous to do quarter-over-quarter comparisons on numbers like our flow, Charles, there's an inherent volatility in it. So I tend to look at it over multiple quarters. But quarter-over-quarter, not much to say in terms of broad demand dynamics, as I said in my prepared remarks, we see the world broadly as we did 3.5 weeks ago when we came and spoke to you guys, in terms of outlook, I'm always a little bit reticent to call quarters before they are closed, but very reticent. But I see no reason why performance shouldn't be broadly in line. That's certainly what we're shooting for.”

asked by Charles Rhyee · answered by Barry Balfe

How will pass-through dynamics play out through the year and impact margins, and what's the expected cash flow cadence?

Pass-through revenues declined by ~$100 million from Q4 to Q1 and are assumed to be broadly stable at Q1 levels for the rest of the year in guidance. Q1 free cash flow was lower YoY, consistent with EBITDA. Q2 free cash flow is typically lower than Q1 due to the timing of interest and tax payments.

“On cash flow, free cash flow, obviously, in Q1 was about $100 million lower than Q1 last year. That's broadly consistent with the EBITDA decrease year-over-year as well, which is about $80 million Q1 to Q2. Our Q1 to Q1, I should say. As we go through the year, I would just -- at a macro level, focus on that EBITDA movement year-over-year.”

asked by Patrick Donnelly · answered by Nigel Clerkin

Given that guidance excludes share repurchases, what is the company's view on buyback potential for 2026 and 2027?

Buybacks are currently constrained due to a closed period but are anticipated to resume in Q3. Management views share buybacks as a top capital allocation priority, pointing to last year's track record of spending almost all free cash flow on buybacks.

“So you're right, the guidance excludes any benefit from buybacks. So as a reminder, we currently are not able to do buybacks because of the delay in publishing our year-end results has meant we have not actually been able to enter into an open period yet, and we're still in a close period until we publish our Q2 results. But we would anticipate being in a position of being able to go back to start buybacks again in the third quarter.”

asked by Ann Hynes · answered by Nigel Clerkin

How has the hybrid FSP/FSO strategy impacted the mix, and why does it lead to an expectation of a greater proportion of direct fee revenue?

The hybrid strategy allows ICON to optimize interfaces with customers, offering flexibility and continuity of experience. By being a better partner and integrating solutions, ICON aims to capture more work, including full-service and stand-alone projects, which ultimately drives a greater proportion of direct fee revenue over the long term.

“So for me, it's about not taking anything off the table. Perhaps the most topical way of thinking about this for FSP customers is the CRO industry for far too long, at a nasty habit of saying, you don't get my toys if you're not outsourcing the way I want you to. You don't get anything both the people if you're in an FSP model. And we think that's math. I think I said on our last call that we don't just want to be the best delivery engine in the business. We want to be the best partner in the business. And that's really at the core of how we try and differentiate.”

asked by Ryan Halsted · answered by Barry Balfe